

# ASX ANNOUNCEMENT

1 December 2021

## DurAVR™ FIRST IN HUMAN PATIENT STUDY FOLLOW UP

**Brisbane, Australia and Minneapolis, USA**, Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company), is pleased to announce that all 5 patients in the first in human DurAVR™ study have passed the 7-day follow up.

All five patients have been assessed and their performance status is excellent.

“ Our patients have passed the 7-day follow up period and all patients are doing well. We are pleased to see our early observations during the procedures continue and the patient’s clinical status is excellent. The next milestone will be the 30 day follow up and we look forward to reviewing the patients at that time” commented Dr Chris Meduri CMO.

“With the 7 day follow up now passed, we are excited to see all patients are benefiting from the DurAVR™ valve. Most of these patients had very poor performance status prior to receiving DurAVR™ and we are very pleased to be able to bring this life changing solution to them in this study. The 30 day follow up will be an important marker and give us clear insights as to how beneficial DurAVR™ has been in these patients from a clinical perspective” commented Wayne Paterson CEO.

**ENDS**

### About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Our focus is on developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris Technologies Ltd's DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

#### Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

#### Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



### Authorisation and Additional information

This announcement was authorised by **Mr Wayne Paterson, Chief Executive Officer.**

### For more information:

Hannah Howlett

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 4 5064 8064

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](https://www.facebook.com/AnterisTech)